BRAIN Biotech P/S 2024

BRAIN Biotech P/S

0.92

BRAIN Biotech Dividend yield

Ticker

BNN.DE

ISIN

DE0005203947

WKN

520394

As of May 10, 2024, BRAIN Biotech's P/S ratio stood at 0.92, a -50.54% change from the 1.86 P/S ratio recorded in the previous year.

The BRAIN Biotech P/S history

BRAIN Biotech Aktienanalyse

What does BRAIN Biotech do?

The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide. The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs. BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas: 1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol. 2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries. 3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion. BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production. An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency. Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production. In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications. BRAIN Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding BRAIN Biotech's P/S Ratio

BRAIN Biotech's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing BRAIN Biotech's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating BRAIN Biotech's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in BRAIN Biotech’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about BRAIN Biotech Stock

What is the price-to-earnings ratio of BRAIN Biotech?

The price-earnings ratio of BRAIN Biotech is currently 0.92.

How has the price-earnings ratio of BRAIN Biotech changed compared to last year?

The price-to-earnings ratio of BRAIN Biotech has increased by -50.54% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of BRAIN Biotech high compared to other companies?

Yes, the price-to-earnings ratio of BRAIN Biotech is high compared to other companies.

How does an increase in the price-earnings ratio of BRAIN Biotech affect the company?

An increase in the price-earnings ratio of BRAIN Biotech would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of BRAIN Biotech affect the company?

A decrease in the price-earnings ratio of BRAIN Biotech would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of BRAIN Biotech?

Some factors that influence the price-earnings ratio of BRAIN Biotech are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does BRAIN Biotech pay?

Over the past 12 months, BRAIN Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BRAIN Biotech is expected to pay a dividend of 0 EUR.

What is the dividend yield of BRAIN Biotech?

The current dividend yield of BRAIN Biotech is .

When does BRAIN Biotech pay dividends?

BRAIN Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BRAIN Biotech?

BRAIN Biotech paid dividends every year for the past 0 years.

What is the dividend of BRAIN Biotech?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is BRAIN Biotech located?

BRAIN Biotech is assigned to the 'Commodities' sector.

Wann musste ich die Aktien von BRAIN Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BRAIN Biotech from 5/10/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/10/2024.

When did BRAIN Biotech pay the last dividend?

The last dividend was paid out on 5/10/2024.

What was the dividend of BRAIN Biotech in the year 2023?

In the year 2023, BRAIN Biotech distributed 0 EUR as dividends.

In which currency does BRAIN Biotech pay out the dividend?

The dividends of BRAIN Biotech are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The BRAIN Biotech stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von BRAIN Biotech

Our stock analysis for BRAIN Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BRAIN Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.